Eli Lilly and Company (LLY) Stock Analysis — March 2026
Company Overview
Eli Lilly and Company is a global pharmaceutical corporation engaged in the discovery, development, manufacturing, and marketing of human medicines across the United States, Europe, China, Japan, and other international markets. The company's product portfolio includes treatments for diabetes such as Basaglar and Humalog series, and it is also heavily focused on developing innovative new drugs, including obesity treatments.
Key Metrics
| Metric | Value |
|---|---|
| Current Price | $917.48 |
| Market Cap | $821.2B |
| PER | 42.92 |
| Forward PER | 23.48 |
| PBR | 33.22 |
| ROE | 101.2% |
| ROA | 19.4% |
| Dividend Yield | 0.6% |
| Operating Margin | 44.9% |
| Revenue Growth | 42.6% |
| Earnings Growth | 51.4% |
| Debt-to-Equity Ratio | 165% |
Valuation Analysis
Eli Lilly's Price-to-Earnings (PER) ratio stands at 42.92x, which is significantly lower than the healthcare sector's average PER of 85.6x. This suggests a potential undervaluation relative to the company's growth prospects. However, its Price-to-Book Ratio (PBR) of 33.22x is high when compared to the sector average of -2.43x. This elevated PBR is likely a reflection of the company's exceptionally high profitability and asset efficiency. The Forward PER of 23.48x indicates market expectations for future earnings improvements.
Growth & Profitability
The company demonstrates robust growth with a revenue growth rate of 42.6% and an earnings growth rate of 51.4%. Eli Lilly's Return on Equity (ROE) is an exceptional 101.2%, showcasing highly efficient utilization of shareholder capital. The strong operating margin of 44.9% and net profit margin of 31.67% underscore its outstanding profitability, driven by strong pricing power and operational efficiency. The Trailing Twelve Months (TTM) Earnings Per Share (EPS) growth of 95.89% further bolsters this positive outlook.
Recent News & Issues
- On March 18, 2026, Lilly's stock experienced a decline amid bearish sentiment from Wall Street.
- On March 17, 2026, HSBC issued a sell recommendation for Lilly, citing potential price reductions for its obesity drugs.
- On March 12, 2026, Jim Cramer highlighted that Lilly's obesity drug approval is imminent, marking a critical milestone for the company.
- On March 11, 2026, TD Cowen downgraded Novo Nordisk to 'Hold' due to the risk of patent expiration for key components of its obesity treatments.
Risk Factors
- Drug Development and Regulatory Risks: The possibility of failure in drug development processes and delays or rejections from regulatory bodies in various countries can directly impact the company's growth trajectory.
- Intensifying Competition: Increased competition from rivals launching new drugs and engaging in price wars within key therapeutic areas, such as the obesity drug market, could pressure profitability.
- Pricing Pressure: Societal and political pressure for price reductions on high-cost medications, including obesity drugs, may lead to decreased revenues and margins.
Overall Assessment
Eli Lilly holds a dominant position within the healthcare sector, characterized by exceptional profitability and high growth rates. Its current valuation appears attractive relative to sector averages, and with a strong drug pipeline and market leadership, continued growth is anticipated. However, careful monitoring of evolving regulatory and competitive landscapes is essential.
This analysis is AI-generated for reference only, not investment advice.